Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. Issue 10145 (4th August 2018)

• Record Type: Journal Article
• Authors: Jankowski, Janusz A Z; de Caestecker, John; Love, Sharon B; Reilly, Gavin; Watson, Peter; Sanders, Scott; Ang, Yeng; Morris, Danielle; Bhandari, Pradeep; Attwood, Stephen; Ragunath, Krish; Rameh, Bashir; Fullarton, Grant; Tucker, Art; Penman, Ian; Rodgers, Colin; Neale, James; Brooks, Claire; Wise, Adelyn; Jones, Stephen; Church, Nicholas; Gibbons, Michael; Johnston, David; Vaidya, Kishor; Anderson, Mark; Balata, Sherzad; Davies, Gareth; Dickey, William; Goddard, Andrew; Edwards, Cathryn; Gore, Stephen; Haigh, Chris; Harding, Timothy; Isaacs, Peter; Jackson, Lucina; Lee, Thomas; Lim, Peik Loon; Macdonald, Christopher; Mairs, Philip; McLoughlin, James; Monk, David; Murdock, Andrew; Murray, Iain; Preston, Sean; Pugh, Stirling; Smart, Howard; Soliman, Ashraf; Todd, John; Turner, Graham; Worthingon, Joy; Harrison, Rebecca; Barr, Hugh; Moayyedi, Paul;
• Is Part Of: Lancet. Volume 392:Issue 10145(2018)
• Page Start: 400
• Page End: 408
• Publication Date: 2018-08-04
• Subjects: Medicine -- Periodicals; Medicine -- Periodicals; Medicine; Medicine; Electronic journals; Periodicals; 610.5
• DOI: 10.1016/S0140-6736(18)31388-6
• Languages: English
• ISSNs: 0140-6736

Abstract

Summary: Background: Oesophageal adenocarcinoma is the sixth most common cause of cancer death worldwide and Barrett's oesophagus is the biggest risk factor. We aimed to evaluate the efficacy of high-dose esomeprazole proton-pump inhibitor (PPI) and aspirin for improving outcomes in patients with Barrett's oesophagus. Methods: The Aspirin and Esomeprazole Chemoprevention in Barrett's metaplasia Trial had a 2 × 2 factorial design and was done at 84 centres in the UK and one in Canada. Patients with Barrett's oesophagus of 1 cm or more were randomised 1:1:1:1 using a computer-generated schedule held in a central trials unit to receive high-dose (40 mg twice-daily) or low-dose (20 mg once-daily) PPI, with or without aspirin (300 mg per day in the UK, 325 mg per day in Canada) for at least 8 years, in an unblinded manner. Reporting pathologists were masked to treatment allocation. The primary composite endpoint was time to all-cause mortality, oesophageal adenocarcinoma, or high-grade dysplasia, which was analysed with accelerated failure time modelling adjusted for minimisation factors (age, Barrett's oesophagus length, intestinal metaplasia) in all patients in the intention-to-treat population. This trial is registered with EudraCT, number 2004-003836-77. Findings: Between March 10, 2005, and March 1, 2009, 2557 patients were recruited. 705 patients were assigned to low-dose PPI and no aspirin, 704 to high-dose PPI and no aspirin, 571 to low-dose PPI and aspirin, and 577 to high-dose PPI and aspirin. Median follow-up and treatment duration was 8·9 years (IQR 8·2–9·8), and we collected 20 095 follow-up years and 99·9% of planned data. 313 primary events occurred. High-dose PPI (139 events in 1270 patients) was superior to low-dose PPI (174 events in 1265 patients; time ratio [TR] 1·27, 95% CI 1·01–1·58, p=0·038). Aspirin (127 events in 1138 patients) was not significantly better than no aspirin (154 events in 1142 patients; TR 1·24, 0·98–1·57, p=0·068). If patients using non-steroidal anti-inflammatory drugs were censored at the time of first use, aspirin was significantly better than no aspirin (TR 1·29, 1·01–1·66, p=0·043; n=2236). Combining high-dose PPI with aspirin had the strongest effect compared with low-dose PPI without aspirin (TR 1·59, 1·14–2·23, p=0·0068). The numbers needed to treat were 34 for PPI and 43 for aspirin. Only 28 (1%) participants reported study-treatment-related serious adverse events. Interpretation: High-dose PPI and aspirin chemoprevention therapy, especially in combination, significantly and safely improved outcomes in patients with Barrett's oesophagus. Funding: Cancer Research UK, AstraZeneca, Wellcome Trust, and Health Technology Assessment.